Prostatilen Research for Chronic Prostatitis
An evidence-based overview of research examining Prostatilen in the context of chronic prostatitis. This page synthesizes findings from peer-reviewed literature.
Research Summary
Prostatilen is registered in Russia specifically for chronic prostatitis treatment. Multiple Russian clinical studies report reduced inflammatory markers, improved urinary symptoms, and decreased pain scores. Most studies are open-label or poorly controlled by Western standards. No independent Western validation exists.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Chronic Prostatitis
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Prostatilen may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.